Compare Davita Inc (DVA) vs Expedia Group Inc (EXPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Expedia Group Inc — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while Expedia Group Inc trades at $321.16 (market cap $37.69B). The key difference: Expedia Group Inc is far larger — about 3.2× Davita Inc's market cap, and Expedia Group Inc pays a 0.61% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | EXPE | |
|---|---|---|
Market Cap | $11.72B | $37.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $321.07 |
52-Week Low | $103.87 | $188.51 |
Enterprise Value | $24.44B | $36.25B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Expedia Group (EXPE) trades at $310.68, up 1.34% on the day, with a bullish technical signal supported by moving averages and strong quarterly earnings beats. The company reported Q2 2026 EPS of $5.76, exceeding expectations, driven by 14% revenue growth and robust B2B performance. Valuation metrics include a P/E of 19.54 and P/S of 2.51, with net income margin improving to 12.97% in 2025. Recent news highlights AI integration and raised full-year guidance, reflecting operational strength.
The outlook for EXPE is positive, with earnings momentum and strategic expansions offering upside potential, though high debt levels and travel industry volatility pose risks. Analysts project a consensus price target of $322.95, with 47% buy ratings, indicating cautious optimism. Investors should weigh solid fundamentals against macroeconomic sensitivities affecting travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
